LH

Labcorp Holdings (NYSE: LH) partnered with Waters Corporation to deploy the BD Onclarity HPV Assay across its national laboratory network.

Labcorp stock barely flinched after its Q3 2026 release, ticking around 0.6% higher near US$362 even as the company posted a muscular quarter.

Shares of healthcare diagnostics company Labcorp Holdings (NYSE:LH) jumped 10.3% in the afternoon session after the company reported third-quarter financial results that were above Wall Street expectations and raised its full-year forecast.

(LH) on Wednesday reported third-quarter earnings of $262.The Burlington, North Carolina-based company said it had profit of $3.

Labcorp raised its FY2026 revenue and earnings forecasts following a Q3 beat, while Chemed attracted an analyst upgrade after its VITAS business drove Q3 earnings growth.

Moby summary of Labcorp Holdings Inc.'s Q3 2026 earnings call

Labcorp (NYSE:LH) reported third-quarter 2026 revenue growth, margin expansion and double-digit adjusted earnings-per-share growth, prompting the laboratory services company to raise the midpoint of its full-year revenue and earnings outlook.

Labcorp Holdings Inc. (NYSE:LH) shares advanced 1.

Labcorp shares rise as Q3 earnings and revenues beat estimates, both segments deliver growth, margins expand and the company raises its 2026 financial outlook.

Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Labcorp (LH) delivered earnings and revenue surprises of +2.80% and +1.13%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?